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ABSTRACT
 
The ability of the indirect dopamine agonist, amphetamine,
 
to produce behavioral sensitization was assessed in adult
 
DiA-deficient and wild-type mice. It was originally
 
predicted that: 1) dopamine (DA) Di-like receptors are
 
necessary for the occurrence of short- and long-term
 
amphetamine-induced behavioral sensitization, 2) DA Di-like
 
receptors are necessary for environmental conditioning
 
factors associated with amphetamine-induced behavioral
 
sensitization, and 3) DA D5 receptors are required for
 
amphetamine-induced behavioral sensitization. Locomotor
 
activity and stereotyped sniffing were assessed in each of
 
three experiments.
 
In Experiment 1, adult wild-type and DiA-deficient mice
 
were injected with amphetamine (1.0, 2.0, 4.0, or 8.0
 
mg/kg, i.p.) or saline for seven consecutive days and then
 
challenged with amphetamine after three and seventeen
 
abstinence days. In Experiment 2, wild-type and Dia­
deficient mice were injected with amphetamine (8.0 mg/kg,
 
i.p.) or saline in either their home cage or testing
 
chamber for seven consecutive days. Mice were then
 
challenged with amphetamine (1.0 mg/kg, i.p.) after three
 
abstinence days to determine whether the Dia receptor is
 
iii
 
necessary for the environmental conditioning factors
 
associated with amphetamine-induced behavioral
 
sensitization. After an additional day, all mice were
 
challenged with saline to determine the influence of the Dia
 
receptor on conditioned activity. In Experiment 3, wild-

type and DiA-deficient mice were co-administered the DA Di-

like antagonist SCH-23390 (0.15, 0.50, or 1.5 mg/kg, i.p.)
 
and either amphetamine (8.0 mg/kg, i.p.) or saline for
 
seven consecutive days. Mice were then challenged with
 
amphetamine (1.0 mg/kg, i.p.) in the testing chamber after
 
three abstinence days to determine whether the D5 receptor
 
is important for amphetamine-induced behavioral
 
sensitization.
 
The results of the first experiment showed that the
 
DiA-receptor is not necessary,for short- and long-term
 
amphetamine-induced behavioral sensitization. In the
 
second experiment, DiA-deficient mice were not found to be
 
heavily influenced by drug-paired cues (Pavlovian
 
associations), but they did show pronounced conditioned
 
activity when compared to wild-type controls. Results from
 
the third experiment determined that the Di-like receptor is
 
necessary for amphetamine-induced behavioral sensitization
 
in wild-type mice, but that neither Dia nor D5 receptors are
 
iv
 
required for amphetamine-induced behavioral sensitization
 
in DiA-deficient mice. When taken together, these results
 
indicate that DiA-deficient and wild-type mice are both able
 
to express amphetamine-induced behaviora1 sensitization.
 
Wild-type mice require the Di-like receptpr to express
 
amphetamine-induced behavioral sensitization, whereas Dia­
deficient mice apparently developed a compensatory
 
mechanism which enables them to express amphetamine-induced
 
behavioral sensitization independent of both Dia and D5
 
receptors. The nature of this compensatory mechanism is
 
not yet understood.
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INTRODUCTION.
 
, It is now weli estabiished that dopam (DA) has
 
intimate ties with the basic underlying neurobiological
 
mechanisms of drug,,, addiction.TTn .faGt, the DA^^ , :
 
neurotransmitter system n^^ . only mediates'reward., but.also
 
the locomotor activating effects of various drugs of abuse.
 
Several studies suggest that DA is the main
 
neurotransmitter associated with reward and reinforced : ■ 
responding (Kalivas & Stewart, 1991; Nestler, 1992;
 
Robinson & Becker, 1986; Robinson & Berridge, 1993; Wise &
 
.Bozarth, 1984). For example, various psychostimulants, such
 
as cocaine and amphetamine, augment locomotor activity and
 
reward by indirectly increasing DA concentrations in the
 
synapse (Reith, Sershen, & Lajtha, 1980). This increase in'
 
, DA has been shown to exert a euphoric-like effect, as well
 
as induce other motivational factors associated with drug
 
craving (Robinson & Berridge, 1993); and, consequently, , , ;
 
psychostimulants are subject to abuse (Robinson & Berridge,
 
,1993; Wise .fc/Bozarth,: 1987).
 
Dopamine Pathways and Input/Output Structures
 
Psychostimulant drugs, like amphetamine and cocaine,
 
increase DA in the synapse by either blocking or reversing
 
the DA reuptake pump. More specifically, cocaine
 
 indirectlY augments DA levels by blocking the DA reuptake 
pump, therefore enabling synaptic DA to persist in the 
synapse longer (Relth et al., 1980). Amphetamine reverses 
the reuptake pump, thus transporting newly synthesized;,DA 
into the synapse (Seiden, Sabbl, & Ricuarte, 1993). As key 
systems regulatihg reward and behavioral activity, the ■ 
mesolimbic and nigrostriatal DA pathways appear to be
 
primary sites of action for psychostimulant drugs. (Wise &
 
Bozarth,. 1984). .) /
 
Mesolimbic Dopamine Pathway
 
, The mesolimbic DA pathway is comprised of cell bodies
 
in the ventral tegmental area which have axons that project
 
from this midbrain structure to an area in the forebrain,
 
known as the striatiim (see Figure 1) (Pierce & Kalivas,
 
1997; Wise & Bozarth, 1987). The most anterior portion of
 
the Striatum is a structure commonly referred to as the
 
nucleus accumbens (or ventral striatum). Fibers which ;
 
originate in the ventral tegmental area and terminate in
 
the nucleus accumbens modulate GABA-ergic efferefits . '
 
projecting to the prefrontal cortex and substantia nigra
 
(Bedingfield, Calder, Thai., & Karler,, ,1997; Karler,
 
Bedingfield, Thai," & Calder, 199.7; Pierce & Kalivas, 1997; ;
 
Smith & Bolam, 1990). Psychostimulant-induced modulation of
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Figure 1. Mesolimbic Dopamine Pathway. DYN = Dynorphin; DA = 
Dopamine; k = K-Opioid; receptors; GABA = y-Amino Butyric Acid; EAA 
Excitatory Amino Acid. 
the mesolimbic DA tract has been theorized to mediate
 
behavioral (i.e., locomotor) activity and the subjective
 
effects of reward (Wise & Bozarth, 1987).
 
Evidence Indicating That Psychostimulant Drugs Affect the
 
Mesolimbic Dopamine Pathway
 
DA receptors in the nucleus accumbens are stimulated
 
by psychostimulant drugs through two mechanisms (Bjijou,
 
Stinus, Le Moal, & Cador, 1995); Vezina, 1993; 1996).
 
First, intra-cranial infusion of amphetamine into the
 
ventral tegmental area produces an augmented concentration
 
of DA in the nucleus accumbens (Vezina, 1993; 1996).
 
Second, microinjecting cocaine or amphetamine into the
 
nucleus accumbens produces robust behavioral activity by
 
indirectly increasing DA levels (Delfs, Schreiber, &
 
Kelley, 1990). Lesioning the nucleus accumbens
 
substantially reduces behavioral activity induced by
 
systemic amphetamine injections (Kelly & Iversen, 1976).
 
Since psychostimulant drugs have a high abuse
 
potential in humans (Di Chiara, 1998; Robinson & Berridge,
 
1993) it is not surprising that intravenous self-

administration of psychostimulant drugs has been intensely
 
studied in animals. To this end, animals will readily self-

administer amphetamine or cocaine directly into the nucleus
 
accumbens or the ventral tegmental area (Collins, Weeks,
 
Cooper, Good, & Russell, 1984; Schuster & Thompson, 1969).
 
When the mesolimbic DA system is lesioned by 6­
hydroxydppamine (6-OHDA) or kainic acid, self­
adminisbration of cocaine (Pettit, Rttenberg/ Bloom,- & '
 
Koob, 1984; Roberts, Koob, Klonoff, & Fibiger, 1980) or
 
amphetamine (Lyness, Friedle, & Moore, 1979) is abolished.
 
Clearly then, DA receptor stimulation in the mesolimbic
 
pathway mediates cocaine and amphetamine self-

administration.
 
Nigrostriatal Dppamine;Pathway
 
(C ; /A opposed to the mesolimbic DA pathway, the
 
nigrostriatal DA pathway primarily mediates behavioral
 
stereotypy (Arnt, 1987). The nigrostriatal DA pathway
 
includes two primary brain areas: the substantia nigra and
 
the caudate/putamen (also called the dorsal striatum; see
 
Figure 2). Specifically, DA neurons project from the
 
substantia nigra to the caudate/putamen; Clark & White,
 
1987; Pierce & Kalivas, 1997). Accordingly then, DA
 
receptors in the caudate/putamen are indirectly stimulated
 
by psychostimulant drugs and, as a result, cause behavioral
 
stereotypy.
 
Evidence Indicating That Psychostimulant Drugs Affect the
 
 Caudate/Putamen
 
(Dorsal Striatum)
 
DADA DAD
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Figure 2. Nigrostriatal bopamine Pathway. DYN = Dynorphin; DA
 
Dopamine; K = K-Opioid receptors; GABA = y-Amino Butyric Acid.
 
Nigrostriatal Dopamine Pathway
 
DA receptors in the caudate/putamen are indirectly
 
stimulated by psychostimulant drugs (Dickson, Lang, Hinton,
 
& Kelly 1994; Statoni Solomon, 1984). Systemic
 
,administration of lower doses of amphetamine preferentially
 
induces locomotor activity, presumably because of increased
 
DA receptor stimulation in the nucleus accumbens. In
 
contrast, systemic administration of higher doses of
 
amphetamine produces stereotyped behaviors via stimulation
 
of the caudate/putamen (Clark & White, 1987; Sharp,
 
Zetterstrom, Ljungberg, & Ungerstedt, 1987). In fact,
 
microinjecting amphetamine into the caudate/putamen induces
 
intense oral stereotypies, consisting of bar biting, non-

injurious self-biting and repetitive paw-to-mouth movements
 
(Dickson et al., 1994), whereas microinjecting amphetamine
 
into the nucleus accumbens only produces locomotor activity
 
(Staton Sc Solomon, 1984).
 
Similarly, Stahl and colleagues have shown, using
 
electroencephalograph (EEG) pattern recognition, that
 
amphetamine affects different brain regions depending on
 
dose administered (Stahl, Ferger, & Kuschinsky, 1997). In
 
terms of stereotypy, low versus high doses of amphetamine
 
cause a shift of activation from the mesolimbic DA system
 
to the nigrostriatal DA system, respectively (Stahl et al.,
 
1997), Additionally, other researchers suggest an additive
 
relationship between the DA systems. Chronic amphetamine
 
treatment produces augmented DA release in the nucleus
 
accumbens and thereby induces locomotor activity and
 
rearing (Robinson, Jurson, Bennett, & Bentgen, 1988),
 
whereas the same chronic treatment produces augmented DA
 
release in the caudate/putamen, resulting in intense oral
 
stereotypies (Kelly, Seviour, & Iversen, 1975; Patrick,
 
Thompson, Walker, & Patrick, 1991).
 
Dopamine Receptor Classification
 
As study of the DA neurotransmitter system progressed,
 
the initial classification of DA receptors was revised to
 
include a number of DA receptors subtypes. Generally, DA.
 
receptors belong to a class of seven-transmembrane domain,
 
G-protein-coupled receptors (Seeman & Van Tol, 1994;
 
Sokoloff & Schwartz, 1995). Based on sequence homology
 
studies, six DA receptors have been cloned: Dia, D2S/ D2l/ D3,
 
D4, and D5 (D5 is sometimes referred to as Dib) (Seeman & Van
 
Tol, 1994; Sokoloff & Schwartz, 1995). These receptors can
 
be separated into two subfamilies, Di-like and D2-like,
 
based on the original biochemical classification of
 
Kebabian and Calne (1979). The Di-like receptor family
 
includes the Di and D5 receptors, whereas the D2 family
 
includes the Das/ D2L/ D3, and D4 receptors (Clark & White,
 
1987).
 
As the importance of these subtypes became known,
 
pharmacological.compounds for these DA receptor subtypes
 
were developed. Using selective DA agonists and
 
antagonists, a number of receptor-specific behavioral
 
profiles have been determined. For example, Di-like
 
receptor stimulation dramatically augments grooming,
 
rearing, and non-stereotyped locomotor activity, yet has
 
little effect on yawnihg and, sniffing (Arnt, 1987; Braun &
 
Chase, 1986; Molloy & Wadding;ton, 1987). On the other hand,
 
D2-like receptor activation produces stereotyped locomotor
 
activity, yawning and sniffing;(Arnt, 1987,; Johansspn, :
 
Levin, Gunne, & Ellison, 1987; Longoni, Spina, & Di Chiara,
 
1987; White) Bednarzi IJjoith, &,Broocierson, ; l988);i
 
In addition, Di-like receptor stimulation by SKF-38393 (a
 
Di-like receptor agonist) induces lodomot
 
activity, while quinpirole-induced stimulation of Ds^like
 
receptors produces only stereotyped locomotor activity and
 
sniffing (Page & Terry, 1997; Hooks et ai., 1994:)- Systemic
 
injections of I^-propylyorapomorphine (NBA; a full dopamine
 
receptor agonist) induce, robust stereotypy with minimal,
 
loCoraotor activity■ (Bordi, Carr, & Meller> i989) .
 
Logically then, Clark and White'' f(1987) hypothesized that Di-

like receptors mediate low-intensity behaviors, but ' t,' 
hypothesized that high-intehsity behaviors require the co-
activation of both Di-like and D2-like receptors. 
Other studies indicate that tonic activation of Di-like 
receptors is essential for the full behavioral expression 
of Da-like receptor mediated behaviors. Accordingly, Molloy 
and Waddington (1987) have shown that antagonizing Di-like 
receptors with SCH-23390 attenuates Dalike agonist-induced 
locomotion. Di-like receptor-mediated behaviors, on the 
other hand, do not need co-activation of Da-like receptors 
(White et al., 1988) . To affirm this. Da-like receptor 
blockade failed to influence Di-like receptor-mediated 
behaviors, perhaps indicating a one-way synergistic role 
between the Di and Da receptor families (White et al., 
1988) . 1' ' ' ' ^ ^ '•1 
Brain Structures Associated With Dj-Like and Da^Like; , , 
Receptor-Mediated Behaviors 
Although stimulation of DA receptors induces a wide 
range of behaviors, several DA receptor-specific behaviors 
have been linked to particular brain areas. As such, Di­
 like,receptor-mediated behaviors, (grdoming, rearing:: and
 
locomotor activity) are thought to be induced via
 
stimulation of .the nucleus accumbens, while D2-like
 
receptor-mediated behaviors (stereotyped sniffing and
 
yawning) are thought to be primarily induced through
 
■stimulation of the caudate/putamen (Bordi et al., 1989; 
Deifs et al., 1990; Dickson et al., 1994; Staton & Solomon, 
'198,4) . ■ .vi- y; , 
Psychostimulant drugs induce many of the same 
behaviors that are produced by DA Di-like- and. D2-like­
receptor agonist drugs. In fact, low doses of amphetamine 
elicit locomotor activity and sniffing, whereas higher 
doses tend to reduce locomotor activity while promoting 
intense oral stereotypies (Kelly, Sevipur, & Iversen, 
1975) . As a result, amphetamine displays a broad behavioral 
profile, as it can produce different intensities of . 
behavior in a dose-dependent manner (Dickson et al., 1994) . 
' , Through EEG pattern recognition, Ferger, Kropf, and 
Kuschinsky (1994) revealed that cocaine and amphetamine 
preferentially affect Di-like receptors. Thus acute 
treatment with low doses of amphetamine produce EEG 
patterns precisely resembling Di-like receptor agonist EEG 
patterns, suggesting mesolimbic DA system activity. After 
■ 11 
repeated amphetamine injections, or after an acute
 
injection with a high dose of amphetamine, both Di-like and
 
D2-like receptor EEG patterns were evident, suggesting a
 
synergistic relationship between mesolimbic and
 
nigrostriatal systems. These results are consistent with
 
other studies showing that low doses of amphetamine and
 
cocaine produce low-intensity behaviors, such as locomotor
 
activity and rearing (a Di-like effect), whereas high doses
 
produce high-intensity behaviors, such as oral stereotypies
 
(a combined Di-like and D2-like effect; Clark & White, 1987;
 
White et al., 1988)-. What is more, Di-like receptor EEG
 
patterns were fully attenuated by the DA Di-like receptor
 
antagonist SCH-23390, while D2-like EEG patterns were only
 
reduced (Stahl et al., 1997).
 
Dopamine Dj-Like and D2-Like Receptor Interaction
 
Research suggesting a synergistic interaction between
 
DA Di-like and D2-like receptors implies that stimulation of
 
Di-like receptors somehow 'facilitates' or 'enables' D2-like
 
,receptor-mediated behaviors. Because amphetamine can
 
produce intense stereotypy at high doses (Callaway,
 
Kuczenski, & Segal, 1989; Clark & White, 1987), amphetamine
 
must also stimulate DA D2-like receptors, albeit indirectly.
 
This conclusion is not surprising. In point of fact, both
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spiperone:and sulpiride (Os^like,,reGeptor. antagoiaists) block
 
amphetamine-induced stereotypy, but leave locomotor
 
activity relatively unaffected. This indicates that the Da­
like receptor is necessary for amphetamine-induced
 
stereotypy (Bedingfield et al., 1997).
 
The potent and specific Da-like receptor agonist,
 
quinpirole, induces a wide range of behaviors, like
 
locomotor activity, sniffing and yawning (Dall'Olio,
 
Gandolfi, Vaccheri, Roncada,. & Montanaro, 1988; Longoni et
 
al., 1987; Molloy & Waddington, 1987). Quinpirole-induced
 
behaviors are intensified by the Di-like receptor agonist,
 
SKF-38393, converting normal Da-like receptor-mediated
 
behaviors to more intense and focused forms of stereotypy
 
(licking and gnawing) (Dall'Olio et al., 1988; Starr, 1988;
 
White et al., 1988). In fact, after systemic DA depletion
 
by a-methyl-p-tyrosine (AMPT; a tyrosine hydroxylase
 
inhibitor), quinpirole-induced behaviors are abolished, yet
 
the same behaviors are reinstated when SKF-38393 is
 
administered (White et al., 1988). The reciprocal
 
relationship, however, does not exist, as quinpirole fails
 
to alter SKF-38393-induced grooming, further indicating
 
that Di-like receptor stimulation enables D2-like receptor
 
13
 
 mediated behavior (white et al., 1988).
 
Other neurotransmitter systems (e.g., excitatory amino
 
acids and GABA) modulate amphetamine-induced behaviors.
 
That is, CPP (an NMDA receptor antagonist) and THIP (a GABAa
 
receptor agonist) attenuate amphetamine-induced stereotypy
 
(Karler et al., 1997). Not surprisingly, NMDA and GABAa
 
receptors are co-expressed on nigrostriatal and
 
striatonigral DA neurons, suggesting that the mechanisms
 
mediating amphetamine-induced stereotypy are much more
 
complex than originally thought (Karler, Calder, ChaUdhry,
 
Sc Turkanis, 1989; Karler, Calder, & Tiirkanis, 1991; Pierce.
 
Sc Kalivas, 1997; Wolf & Jeziorski, 1993).
 
In sum, chronic treatment with psychostimulant drugs
 
has been shown to alter dopaminergic, GABA-ergic, and
 
glutaminergic systems (Cador, Bjijou, Cailhol, & Stinus,
 
1999; Vezina, 1993; Vezina & Stewart, 1989; Wolf, 1998).
 
Because these neurotransmitter systems are involved in drug
 
craving, addiction, and reward, the impact of chronic
 
amphetamine treatment on these systems has been intensely
 
investigated. As a result, over the past decade, several
 
theories describing psychostimulant abuse have been
 
developed, most of them focusing on the effects of chronic
 
amphetamine treatment.
 
■ ■ 14 : 
Amphetamine and Sensitization
 
Chronic amphetamine use in humans can result in twp
 
major disorders: drug addiction and amphetamine-induced
 
psychosis (Kalivas & Stewart, 1991; Lett, 1989; Robinson &
 
Becker, 1986; Robinson & Berridge, 1993; Sato, 1986). The
 
most studied is drug addiction, as this phenomenon can be
 
described as a persistent and intense involvement with
 
stress upon a single behavior pattern, with a minimization
 
of exclusion of other behavior patterns. Chronic
 
amphetamine use can also result in a condition called
 
amphetamine psychosis, a state similar to paranoid
 
schizophrenia (Sato, 1986). Although the symptoms of
 
amphetamine psychosis often disappear after cessation of
 
drug taking, craving for the;drug and hypersensitivity to
 
the psychomimetic effects remain for years (Robinson &
 
Berridge, 1993; Sato, 1986).
 
in animal research, a similar phenomenon is termed
 
behavioral sensitization, and it occurs after chronic
 
treatment with amphetamine, cocaine, methylphenidate
 
(Ritalin), methamphetamine and many other psychostimulant
 
drugs (Akimoto, Hamamura, Kazahaya, Akiyama, & Otsuki,
 
1990; Crawford, McDougall, Meier, Collins, & Watson, 1998;
 
Kalivas & Duffy, 1990; McDougall, Collins, Karper, Watson,
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&: Crawford, 1999; Parsons & Justice, 1993; Patrick et al.,
 
1991; Pettit, Pan, Parsons, & Justice, 1990; Wolf, White,
 
NasSar, Broods & Khansa, 1993). Behavioral
 
sensitizatidn is characterized by a progressive and
 
enduring enhancement of drug-induced behavioral effects of
 
psychostimulant compounds (Kalivas & Stewart, 1991;
 
Robinson & Becksr, 1986; Robinson & Berridge,,^^^^^^^l^^^^^
 
specifically, senSitization is viewed ias tho i series
 
of behavioral responses that may lead to drug addiction
 
(Robinson & Berridge, 1993). Accordingly, sensitization
 
has often been depicted as a major component to the animal
 
model of drug addiction, since it has been shown to persist
 
for up to a year after a single drug administration
 
(Paulson, Camp, & Robinson, 1991). Because sensitization
 
has similar characteristics to that of paranoid
 
schizophrenia and the initial stages of drug addiction, a
 
better understanding of the processes involved would prove
 
beneficial (Kalivas & Stewart, 1991; Robinson & Becker,
 
1986; Robinson & Berridge, 1993).
 
Sensitization in Terms of Associative Learning
 
(Environmental Conditioning)
 
Robinson and Berridge (1993) suggests an Incentive-

Sensitization Theory of drug addiction to explain: (1) the
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 intense craving and compulsive drug-seeking behavior or
 
^wanting' of the drug, ad opposed to: 'liking' the drug, (2)
 
why drug craving often persists, and can be reinstated,
 
long after the discontinuation of drug use, and (3) why
 
drug addicts continue to use and 'want' psychostimulant
 
drugs, despite the decreasing pleasurable effects
 
experienced after repeated use (Robinson & Berridge, 1993).
 
The term 'incentive' suggests that while taking
 
psychostimulant drugs, certain stimuli associated with the
 
drug-taking environment become salient and induce a
 
psychological process called 'incentive-salience'. Thus
 
stimuli (e.g., rooms, paraphernalia, friends, smells, etc.)
 
that are continuously, contiguously, and frequently
 
associated with drug-taking become attractive to the user
 
and, therefore, psychologically induce 'craving' and :
 
'wanting' for the drug (Kozlowski & Wilkinson, 1987;
 
Robinson & Berridge, 1993). These powerful incentive
 
stimuli, in turn, create an uncontrollable craving and
 
wanting for the drug, spawning repeated use that may
 
develop into drug addiction (Robinson & Berridge, 1993;
 
Wise, 1988). In essence, the drug-paired environment
 
produces a psychological incentive to take more drug.
 
The Incentive-Sensitization theory indicates that ';: ';
 
■ ■ ■ ■ - ■ V'. ;' ' '' iv l ^ 
repeated bouts of drug-taking produce incremental
 
nduroadaptations in the mesolimbic DA system, rendering it,
 
perhaps, permanently hypersensitive (sensitized) to these
 
drug-associated stimuli (Robinson & Becker, 1986; Robinson
 
& Berridge,^ 1993). Therefore,: drug;-associated stimuli are
 
(perhaps') permanently destined, via these neuroadaptations
 
in the mesolimbic DA system, to induce drug-taking
 
behaviors (Robinson & Berridge, 1993).
 
The foundation under which DA sensitization is built
 
is through the process of associative learning (Robinson &
 
Berridge, 1993). Specifically, the drug-taking environment
 
elicits drug-taking behaviors. Gonsequently, the drug-

associated stimuli imbue the drug-taker with incentive-

salience and therefore make the act of drug-taking
 
attractive and irresistible to the user.
 
This theory posits that repeated drug use does not
 
come from the sensitization of the rewarding effects of the
 
drug, but from the environmental cues that have become
 
associated with drug-taking (Robinson & Berridge, 1993).
 
Granted, psychostimulant drugs produce a euphoric-like
 
effect (Wise & Bozarth, 1987, Wise & Rompre, 1989), however
 
this theory makes a clear distinction between 'wanting'
 
(i.e., craving) and 'liking' (i.e., rewarding) the
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 psychostimulant drug (Robinson & Berridge, 1993).
 
Testimonials of ex-drug abusers reflect this, as they
 
express a generalized dislike for the drug after extended
 
use, but they continue to use the drug and risk everything
 
to obtain the drug, despite the diminishing pleasurable
 
effects of the drug (Robinson & Berridge, 1993; Sato,
 
1986). Therefore, drug addiction may not be sustained via
 
the rewarding characteristics of the drug, but through the
 
craving and wanting which develop as a result of incentive-

salience.
 
Two Other theories of addiction have tried to explain
 
the uncontrollable urge to take drugs: the positive-

reinforcement model and the negative-reinforcement model.
 
Specifically, the negative-reinforcement model posits that
 
drugs are taken to avoid the symptoms of withdrawal,
 
whereas the positive-reinforcement model posits that drugs
 
are taken for their reinforcing effects (Robinson & Becker,
 
1986; Robinsdh & Berridgei j; 1993; Wise & Bozarth, 1987, Wise
 
Sc Rompre, 19S9). Importahbly, both theories cannot explain
 
why abusers relapse even after the symptoms of withdrawal
 
have subsided and after many years of abstinence.
 
Moreover, neither of these theories can explain why
 
previous drug abusers continue to crave their specific
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drug, even though the pleasurable effects of the drug
 
became attenuated (Stewart, de Wit, & Eikelboom, 1984;
 
Wise, 1988).
 
In sum, the incentive-sensitization model clarifies how
 
these long-term drug effects occur: by the process of
 
associative learning. More specifically, with incentive-

salience, the drug-associated stimuli become attractive to
 
the user and this causes repeated use. Through continuous
 
drug use specific neuroadaptations occur in the mesolimbic
 
DA system causing these associations to become permanently
 
hypersensitive (or sensitized). Therefore, the user craves
 
drug-associated stimuli, and not the pleasurable effects of
 
the drugs (as in the positive reinforcement model) or the
 
avoidance of withdrawal symptoms (as in the negative
 
reinforcement model). The importance of associative
 
learning, as suggested by the incentive-sensitization
 
model, is supported by other research, since environmental
 
conditions influence the magnitude of sensitization to
 
psychostimulant compounds (Badiani, Camp, & Robinson, 1997;
 
Campbell & Raskin, 1978; Mattingly & Gotsick, 1989).
 
Conditioning Factors (i.e., Pavlovian Associations) in
 
Amphetamine Sensitization
 
The neuropharmacological actions of amphetamine and
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 cocaine have been well characterized. These drugs
 
substantially increase synaptic DA by their action on the
 
DA transporter (or reuptake pump) (Seiden et al., 1993).
 
Sensitization to these drugs is a result of increased DA in
 
the synapse and, from repeated use, produce
 
neuroadaptations in the neural system where these drugs
 
have their action. However, several reports have argued
 
that behavioral sensitization may develop, not only through
 
the persistent use of psychostimulant drugs, but also by
 
associating the drug-taking environment with drug
 
administration (i.e., Pavlovian Associations) (Anagnostaras
 
Sc Robinson, 1996; Badiani et al., 1997; Badiani,
 
Anagnostaras, & Robinson, 1995; Badiani, Browman, &
 
Robinson, 1995; Campbell & Raskin, 1978; Einat et al.,
 
1996; Hoffman & Wise, 1992; Lienau & Kuschinsky, 1997;
 
Mattingly & Gotsick, 1989). For example, recent work by
 
Robinson and colleagues indicates that the environmental
 
conditions of the testing chamber alter the acute effects
 
of amphetamine and the.magnitude of amphetamine and cocaine
 
sensitization (Badiani, Browman, & Robinson, 1995).
 
Specifically, if the drug treatment is paired with the
 
animal's testing environment (but the home cage environment
 
is different), a greater rate of sensitization would occur
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than if the drug treatment is paired with the home
 
environment (Anagnostaras & Robinson, 1996; Badiani,
 
Anagnostaras, & Robinson, 1995; Badiani, Browman, &
 
Robinson, 1995; Lienau & Kuschinsky, 1997; Mattingly &
 
Gotsick, 1989). This would suggest that environmental cues
 
surrounding the drug treatment have a much stronger
 
influence on the rate of sensitization than what was
 
previously thought. This may be potentially important for
 
sensitization research and drug addiction, since the
 
subjective and behavioral effects of addictive drugs
 
largely depend on the environmental context during drug
 
administration (Badiani, Browman, & Robinson, 1995; Carlin,
 
Bakker, Halpern, & Post, 1972; Chait, 1993).
 
Although environmental conditioning factors may affect
 
the overall strength of sensitization, these cues only act
 
in an additive manner. That is, sensitization still occurs
 
when environmental cues are eliminated, albeit the
 
sensitization is not as robust (Badiani, Browman, &
 
Robinson, 1995). Thus, the environmental cues work in
 
tandem with the effects of the psychostimulant drug to
 
promote craving for the drug (in the human model) or induce
 
a sensitized increase in behavioral responding (as in the
 
animal model).
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The Involvement of Excitatory Amino Acids in Behavioral
 
Sensitization; A Neural Basis of Behavioral Sensitization
 
Historically, sensitization research has focused on
 
the idea that changes in the DA system are responsible for
 
the occurrence of behavioral sensitization (Robinson & ,
 
Becker, 1986; Robinson & Berridge, 1993; Wise & Bozarth,
 
1987). However, recent work has shown that excitatory
 
amino acids (EAAs) may play an important role in the
 
development of behavioral sensitization (Wolf, 1998). In
 
fact, EAAs and DA complement each other in a number of
 
ways. That is, EAAs possess a regulatory function over DA,
 
as antagonism of various EAAs attenuates DA release (KarTer
 
et al., 1989; 1991). What is more, several reports suggest
 
an important role for EAAs in amphetamine- and cocaine-

induced behavioral sensitization, as antagonism of specific
 
EAA subtypes eliminates sensitization to these drugs
 
(Karler et al., 1989; Wolf & Jeziorski, 1993).
 
In her theory, Marina Wolf (1998) posited that DA
 
plays a secondary role to EAAs in behavioral sensitization.
 
Because EAAs exert a regulatory role over DA, EAAs control
 
the underlying circuitry responsible for the development of
 
behavioral sensitization, and therefore make the
 
involvement of DA less significant than previously thought
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(Wolf, 1998). This is not to say that DA is not important
 
for the occurrence of behavioral sensitization, since
 
behavioral sensitization cannot be produced without the
 
presence of endogenous DA (Wolf, 1998).
 
Wolf (1998) provides evidence to support the
 
involvement of EAA neurotransmitter systems in
 
sensitization. Blockade of NMDA receptors by MK-801 (a non­
competitive antagonist of the NMDA glutamate receptor)
 
prevents amphetamine- and cocaine-induced behavioral
 
sensitization in mice (Karler et al., 1989). In fact,
 
blockade of NMDA receptors has also been shown to prevent
 
Di-like agonist-induced sensitization (Wolf, White, & Hu,
 
1994). This evidence clearly supports the involvement of
 
NMDA receptors in amphetamine-induced behavioral
 
sensitization.
 
In addition to NMDA receptors, other glutamate
 
receptor subtypes are important for amphetamine
 
sensitization. For instance, the selective AMPA receptor
 
antagonist 2,S-dihydroxy-S-nitro-T-sulfamoyl­
benzo(f)quinoxalin (DNQX) blocks the development of
 
sensitization to amphetamine-induced stereotypy and
 
locomotor activity (Li, Vartanian, White, Xue, & Wolf,
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1997). In addition, cocaine sensitization was blocked
 
the AMPA receptor antagonist 6,7 dinitroquinoxaline-2,3­
dione (NBQX; Li et al., 1997). Other AMPA antagonists,
 
such as 6-CY"ano-7-nitroqinoxaline-2,3-dione (CNQX), block .
 
expression of cocaine-induced sensitization when
 
microinjected into the core of the nucleus accumbens
 
(Pierce, Bell, Duffy, & Kalivas, 1996).
 
So when this evidence is taken together, EAA and DA
 
neurotransmitters appear to interact when mediating
 
behavioral sensitization, since NMDA and AMPA antagonists
 
block DA agonist-induced behavioral sensitization.
 
The Involvement of Dopamine Dj-Like Receptors in Behavioral
 
Sensitization: A Neural Basis of Behavioral Sensitization
 
In addition to Robinson and Berridge's (1993) and
 
Wolf's (1998) theories on behavioral sensitization, Vezina
 
(1996) has developed a theory of behavioral sensitization
 
that primarily focuses on the importance of the DA Di family
 
of receptors. Paul Vezina (1996) showed that behavioral
 
sensitization to amphetamine can be eliminated by
 
antagonizing the Di family of receptors with the potent and
 
specific Di-like receptor antagonist SCH-23390. According
 
to Vezina's model, amphetamine causes somatodendritic DA
 
release in the ventral tegmental area. This DA stimulates
 
Di-like receptors located on the presynaptic terminals of .
 
EAA and GABA projections synapsing on DA neurons.
 
Therefore, araphetamine indirectly:ah^ the activation of
 
mesolimbic DA neurons by modulating GABA and glutamdte
 
neurotransmission in the ventral tegmental area (Vezina,
 
1996).: h-l''
 
The location and function of DA Di-like receptors
 
establishes their importance for behavioral sensitization,
 
because repeatedly microinjecting amphetamine into the
 
ventral tegmental area: 1) produces a sensitized behavioral
 
response to a systemic challenge of amphetamine (Vezina,
 
1996); 2) produces a significant increase in nucleus
 
accumbens DA when challenged with a systemic injection of
 
amphetamine (Vezina, 1996); 3) produces a sensitized
 
behavioral response to a local infusion of amphetamine into
 
the nucleus accumbens (Kalivas & Duffy, 1993a; 1993b;
 
Vezina, 1996); and 4) does not induce behavioral
 
sensitization when co-administered with SCH-23390 (Bjijou
 
et al., 1996; Pierre & Vezina Vezina, 1996). When
 
taken together, it is clear that amphetamine-induced
 
locomotor sensitization requires the activation of DA Di-

like receptors, thus supporting Vezina's (1996) theory that
 
DA Di-like receptor stimulation in the ventral tegmental
 
area is necessary for the occurrence of amphetamine-induced
 
behavioral sensitization.
 
Currently, the DA Di family of receptors has only two .
 
members: Dia and D5 (or Dib). , As previously indicated,
 
Vezina (1996) hypothesized that the Di family of receptors
 
was responsible for the induction of amphetamine-induced
 
behavioral sensitization. Recent work on the DA Di family
 
of receptors has indicated that both Dia and D5 receptors
 
stimulate adenylyl cyclase activity and have a similar
 
affinity for SCH-23390 (Baldessarini & Tarazi, 1996; Clark
 
& White, 1987). But while the Dia receptor may exist in
 
greater numbers throughout limbic and basal ganglia
 
circuits, the D5 receptor, when compared to the Dia
 
receptor, has a much higher affinity for endogenous DA
 
(Baldessarini & Tarazi, 1996; Kostrzewa, 1995).
 
The likelihood of a DA D5 influence on amphetamine-

induced behavioral sensitization is plausible, since
 
repeated administration of psychostimulants has behavioral
 
impact in DiA-deficient mice. For example, Crawford, Drago,
 
Watson, and Levine (1997) showed that amphetamine initiates
 
less locomotor activity in Dia-deficient mice than wild-type
 
controls during pretreatment, but DiA-deficient mice still
 
exhibited a sensitized response when challenged with a low
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dose of amphetamine three days after pretreatment. DA Dia­
deficient mice also show a lessened responsiveness after
 
acute cocaine trea.tment, as- cocaine-induced hyperactivity
 
was blunted in mice lacking the DA Dia receptor (Miner,
 
Drago, Chamberlain, Donovan, & Uhl, 1995; Xu, Hu, Cooper,
 
Moratalla, Graybiel, White & Tonegawa, 1994). This is
 
important since both amphetamine and cocaine function as
 
indirect DA agonists (Reith et al., 1980). Therefore,
 
these data suggest that the DA Dia receptor is necessary for
 
the induction of amphetamine-induced locomotor
 
sensitization. ■ 
Dopamine D5 Receptor Subtype,in Amphetamine Sensitization
 
The fact that DiA-deficient mice are capable of 
expressing locomotor sensitization (Crawford et al., 1997) 
suggests that the ■ DA D5 receptor may be importantly involved 
in amphetamine-induced sensitization. Previously, it has 
been shown that complete blockade of the DA Di-like receptor 
eliminates the occurrence of amphetamine-induced 
sensitization (Vezina, 1996) and that serotonergic and DA 
D2-like receptor systems are not involved in this 
elimination (Bjijou et al., 1996). Therefore, the DA D5 
receptor may be critically important for amphetamine-
induced behavioral sensitization.
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Genetic Tools For Studying Receptor Function
 
Several lines of research establish the importance of
 
the DA Di-like family of receptors for the occurrence of
 
Amphetamine sensitization (Bjijou et al., 19967 Grawfordet
 
al., 19977 Pierre & Vezina, 1998; Vezina, 1996). Yet
 
because the DA Di family of receptors includes two different
 
receptors, it has been impossible to determine the.precise
 
role that DA Dia and D5 receptors play in amphetamine ­
sehsitization Specifically, available ligands are nbt
 
selective enough to distinguish between the Dia and D5
 
receptors.: Fortunately, a DA Dia receptor deficient mouse
 
was ehgineebed to make the answer to this question more
 
accessible. Therefore, the current project will use the
 
PiA-deficient mouse to assess the importance of DA Dia and D5
 
receptors for amphetamine-induced behavioral sensitization.
 
Summary
 
In general, the results of these studies can be
 
summarized as follows: 1) Drug addiction involves the DA
 
system; 2) Psychostimulants such as cocaine and amphetamine
 
increase DA levels and are often abused; 3) The functioning
 
of the mesolitnbic and nigrostriatal DA systems is
 
influenced by psychostimulants; 4) Psychostimulants
 
indirectly:stimulate DA receptors in the ventral tegmental
 
29
 
 area, which causes augmented DA release in the nucleus
 
accumbens; 5) Destruction of the mesolimbic DA system, :
 
either by lesioning the ventral tegmental area or the
 
nucleus accumbens, prevents cocaine- and amphetamine-

induced locomotor effects; 6) DA Di-like receptor activation
 
mediates locomotor activity and rearing, whereas DA D2-like
 
receptor activation mediates stereotyped behaviors; 7) The
 
induction of amphetamine-induced locomotor sensitization is
 
primarily mediated by actions in the ventral tegmental
 
area, whereas expression of amphetamine-induced behavioral
 
sensitization is primarily mediated by the nucleus
 
accumbens; 8) The induction of amphetamine-induced
 
locomotor sensitization can be blocked by Di-like receptor
 
antagonism; and 9) Persistence of amphetamine-induced
 
locomotor sensitization has been shown in mice lacking the
 
Dia receptor. When taken together, these findings suggest
 
the involvement of the DA Di family of receptors in
 
amphetamine-induced behavioral sensitization.
 
Hypothesis
 
Therefore, I proposed that: 1) the DA Di-like receptor
 
is critically important for the induction and long-term
 
expression of amphetamine-induced behavioral sensitization,
 
2) environmental conditibning factors associated with
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amphetamine sensitization are negatively impacted by the 
lack of the Dia receptor; and ■3): . 'p SCH-2339G 
would .block amphetamine-induced behavioral- sensitization in 
piA-deficient mice>. .indicating that- the Dg receptor is 
important for the'occurrence of amphetamipe-induGed 
locomotor sensitization. 
Experimental Plan : ' 
To test.these ideas, .liGonducted three experiments. 
In the first experiment, I injected DiA-deficient and wild-
type mice with various doses of amphetamine or saline for 
seven consecutive days. I challenged these mice with . 
amphetamine after three and seventeen abstinence days. 
This experiment determined whether the DA Dia receptor was . 
responsible for short- and long-term amphetamine-induced 
behavioral sensitization. In the second experiment, I 
manipulated the conditioning environment. Specifically, ­
half the DiA-deficient and wild-type mice received 
amphetamine in the home cage for seven days and the other 
half received amphetamine in the testing chamber for seven 
days. After three abstinence days, I challenged all 
animals with amphetamine in the activity chamber. On the 
following day, I challenged all mice with saline to assess ■ 
conditioned activity. This experiment determined whether 
environmental conditioning factors influenced amphetamine-

induced sensitization of DiA-deficient and wild-type mice.
 
In the third experiment, I injected DiA-deficient and wild-

type mice for seven days with varied doses of the Di-like
 
antagonist SCH-23390 or saline 30-min prior to amphetamine
 
treatment. After three abstinence days, I challenged all
 
animals with amphetamine in the activity chamber. This
 
experiment determined whether the DA D5 receptor mediates
 
amphetamine-induced behavioral sensitization.
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 , GENERAL'METHOD
 
Subjects ^ -.V- '
 
Subjects were 271 adult, wild type (+/+) and Dia­
deficient (-/-) C57BL-6 mice. The subjects were bred at
 
California State University, San Bernardino in a room
 
maintained at 22-24°C on a 12-hour light/dark cycle.
 
Litters were culled to a maximum of 12 pups at seven days
 
of age. Mice were housed with their dam and sire until 21
 
days of age after which they were separated by gender until
 
testing. Care was taken to ensure that a nearly equal
 
number of male and female mice were assigned to each
 
treatment group and that no more than one animal from each
 
litter was placed into any particular group. Subjects were
 
conditioned and tested during the light cycle between the
 
ages of 90 and 120 days. The Animal Care and Use Committee
 
at California State University, San Bernardino approved
 
protocol for the experimental procedures.
 
Apparatus 1
 
Behavior was assessed in Coulbourn Instruments, Tru-

Scan Photobeam Activity Chambers (25.5 x 25.5 x 41 cm). The
 
chambers were made of Plexiglas and have two sets of 16
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pulse-modulated infrared photo beams spaced 1.6 cm apart
 
with dark gray removable floor trays and an open top.
 
Drugs ­
S(+)-amphetamine sulphate and SCH-23990 (Research
 
Biochemicals, Natick, MA) were dissolved in saline and
 
injected intraperitoneally (i.p.) at a volume Of 5 ml/kg.
 
Statistical Analysis
 
Repeated measures analyses of variance (ANOVAs) were
 
used for analyzing the locOmptor activity and stereotyped
 
sniffing data. Significant three- and four-way interactions
 
were further analyzed using lower-order ANOVAs. Additional
 
analysis of the data was made using Tukey tests (p < .05).
 
General Procedure
 
In each of the three experiments there were seven
 
conditioning days followed by either one or two challenge
 
days. On drug pretreatment days, all animals were given
 
either amphetamihe or saliner;and then conditioned for 60
 
min. On challenge days, all animals were challenged with
 
either amphetamine or saline to, assess the presence or
 
absence of behavioral sensitization or conditioned activity.
 
Length of the testing sessions and number of drug abstinence
 
days (time between the last drug pretreatment day and the
 
drug challenge day) varied according to the experiment.
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On all pretreatment and test days, behavioral
 
assessment took place immediately after amphetamine or
 
saline treatment. Locomotor activity was recorded
 
continuously across the testing session, whereas stereotyped
 
sniffing was assessed using a fixed interval momentary time
 
sampling method (Cameron, Crosby, & Crocker, 1988).
 
Essentially the presence or absence of stereotyped sniffing
 
was determined in 30-s intervals. After behavioral
 
assessment, all animals were immediately placed back in
 
their home cage and returned to the animal colony room. ;
 
Genotyping
 
Di-deficient mice were generated as described in Drago
 
et al. (1994) from embryonic stem cells, where one of the Di
 
receptor alleles was targeted in vitro by homologous , ' , ' ,
 
recombination. Briefly, a targeting construct containing a
 
neomycin phosphotransferase gene was inserted into a region
 
of the Di receptor gene encoding the fifth transmembrane
 
domain. A gene sequence (0.75 kb) downstream from the
 
insertion site was excised. This excised g sequence :
 
codes for the third intracytoplasmic loop. The insertion of
 
the targeting construct and the removal of the gene sequence
 
generates an inactive gene product. Positive clones were
 
used to create chimeric mice. Chimeric males were then
 
 mated to female C57BL-6 mice to create heterozygotes.
 
Heterozygous mice have one disrupted Di receptor allele,
 
while Di-deficient mice have both alleles .disruphed;^'^^^^^^^
 
type mice have two normal Di receptor alleles) Receptor
 
binding studies indicate that heterozygous mice have fewer
 
than half the typical number of striatal Di-like receptors
 
,(Drago et al., 1994). , Despite the reduced number of Di-

like receptors, heterozygous mice tend to respond like wild-

type controls:on behavioral tasks (Drago, Gerfen, Westphal,
 
Sc Steiner, 1996; Miner et al., 1995).
 
All mice were genotyped using polymerase chain
 
reaction (PGR) as described previously (Bender, Drago, & '
 
Rivkees, 1997; Miner et al., 1995) The genomic DNA for
 
the assays was obtained from tail biopsies (done before any
 
behavioral assessment) and extracted using the PureGene DNA
 
isolation kit (Gentra Systems, Minneapolis, MN). Two
 
independent PGR reactions were performed for genotyping.
 
The first reaction determined the presence of the neomycin
 
containing transgene. This reaction used a forward primer
 
(D1.5; 5'-ctgattagcgtagcatggactttgtc-3') and a reverse
 
primer (PGKl; 5'-tggatgtggaatgtgtgcgag-3'). PGR conditions
 
were 35 cycles of 94°G (20 min), 58°G (20 min), 72°G (1
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m±n)/ followed by 72°C (6 min). PGR products were separated
 
on a 1.5% agarose gel, with a 330 bp band indicating the
 
presence of at least one transgenic allele. The second
 
reaction determined the presence of the normal Di gene. It
 
used a forward primer (JD.27; 5'aaagttccttaagatgtcct-3')
 
and a reverse primer (JD.26; 5'-tggtggctggaaaacatcaga-3').
 
PGR conditions were the same as in the first reaction with
 
the exception that the annealing temperature was 55°G
 
instead of 58°g. The presence of a 350 bp band indicated at
 
least one wild-type allele.
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EXPERIMENT 1
 
Prior research has indicated that the DA Di family of
 
receptors are intimately linked to the induction'of
 
amphetamine sensitization (Bjijou et al., 1996; Crawford et
 
al., 1997; Vezina, 1996) ., More specifically, Crawford et
 
al. (1997) demonstrated that mice lacking the DA Dia receptor
 
exhibited short-term behavioral sensitization to
 
amphetamine, however long-term amphetamine sensitization was
 
not assessed. Therefore, the purpose of the first
 
experiment was to determine whether DA DiA-deficient mice
 
exhibit amphetamine-induced behavioral sensitization after
 
either a short (3-day) or long (17-day) drug abstinence
 
period.
 
Method
 
Subjects. Subjects were 92 C57BL-6 DA DiA-deficient and
 
wild-type mice.
 
Procedure. The apparatus and procedure described in the
 
General Methods were used with the following exceptions.
 
Subjects were injected with amphetamine (1.0, 2.0, 4.0 or
 
8.0 mg/kg, i.p.) or saline for seven consecutive days. Each
 
conditioning session lasted for 60 min. After three
 
abstinence days, a challenge injection (i.p.) of 1.0 mg/kg
 
amphetamine or saline was given to all mice to assess the
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occurrence of short-term amphetamine-induced behav-iofal
 
sensitization. To assess the .occurrence of long-term
 
amphetatiine-induced behavioral sensitization, ^ m^^^^
 
challenged with amphetamine (1.0 mg/kg i.p.) after a 17-day­
drug abstinence period. Locomotor activity and stereotyped
 
sniffing .were assessed for a total of 150 min. In summary,
 
DiA-deficient and wild-type mice received one of the
 
following six sequences (PRETREATMENT/TEST DAY l/TEST DAY 2)
 
of amphetamine or saline during the pretreatment phase and
 
on the first and second test day (doses are in parentheses):
 
SAL/SAD/AMPH, SAL/AMPH/AMPH-, AMPH(1.0)/AMPH/AMPH,
 
AMPH(2.0)/AMPH/AMPH, AMPH(4.0)/AMPH/AMPH, or
 
AMPH(8.0)/AMPH/AMPH.
 
Results ■ 
Drug Pretreatment Phase: Locomotor Activity. Overall,
 
mice pretreated with 4 or 8 mg/kg amphetamine had larger ,
 
distance traveled scores than saline controls (see Figure
 
3) [pretreatment main effect, F(4,82) = 32.57, p < .001;
 
and Tukey tests, £ < .05]. On all seven pretreatment days,
 
wild-type and DiA-deficient mice given 4 mg/kg amphetamine,
 
{filled triangles) exhibited more locomotor activity than
 
saline-pretreated mice (open circles) [wild-t-ype:
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Figure 3. Mean distance traveled (+SEM) of adult wild-type and Dja­
deficient mice (n = 6 - 10 per group) administered saline (SAL) pr 
amphetamine (AMPH; 1.0, 2.0, 4.0, or 8.0 mg/kg, i.p.) for seven 
consecutive pretreatment days. Behavioral assessment. las.ted for 60 min 
and occurred immediately after injection. O .= .SAL; ® = 1.0 mg/kg 
AMPH; ♦ = 2.0 mg/kg AMPH; ▲ = 4.0 mg/kg AMPH; ■ = 8.0 mg/kg AMPH. 
* Significantly different from the SAL group , (p <: .05) . , , , 
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pretreatment x day interaction, F(24,294) = 4.38, £ < .001;
 
PiA-^deficient: pretreatment x day interaction, F(24,198):
 
3.79, £ < .001; and Tukey tests, £ < .05]. Wild-type and
 
Dia"deficient mice pretreated with 8 mg/kg amphetamine
 
{filled squares) had more distance traveled on time blocks
 
1 and 2 than saline controls [Tukey tests, £ < .05].
 
Drug Pretreatment Phase: Stereotyped Sniffing. During
 
the pretreatment phase, mice given 8 mg/kg amphetamine
 
sniffed more than mice given saline (see Figure 4)
 
:[pretreatment main effect, F(4,82) = 12.06, £ < .001; and
 
Tukey tests, £ < .05]. This drug effect varied according
 
to both genotypd and pretreatment day. On day 1, wild-type
 
mice pretreated with 4 or 8 mg/kg amphetamine had more
 
sniffing counts than saline controls; whereas,, wild-type
 
mice given 2 or 8 mg/kg amphetamine had more sniffing
 
counts than saline-pretreated mice on day 7 (see upper
 
graph. Figure 4) [pretreatment x day interaction, F(4,49) =
 
2.87, £ < .05; and Tukey tests, £ < .05]. DiA-deficient
 
mice exhibited a different pattern of effects, because only
 
mice given 8 mg/kg amphetamine sniffed more than saline-

pretreated mice (see lower graph. Figure 4) [pretreatment
 
main effect, F(4,33) = 3.36, p < .05; and Tukey tests, £ <
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Figure 4. Mean stereotypeci sniffing counts (fSElM) of adult wild-type 
and DiA-deficient mice (n = 6 , - 10 per group) administered saline ' (SAL) . 
or amphetamine (AMPH; 1.Qy 2iO> 4.0, or 8.0 mg/kg, i.p. ) for seven ­
consecutive pretreatment days. Behavibral assessmeht lasted for 60 min 
and occurred immediately after injection. G ^ SAL; ® = 1.0 itig/kg 
AMPH;; ♦ - 2 .0 mg/kg AMPH; = 4 . 0 mg/kg; AMPH; ■ 8 : 0 mg/kg AMPH. 
*.Sigriifleantly different from the SAL group (p < . 05) . 
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 Test Day Locomotor Activity: :Three Abstinence Days> On
 
time blocks 1-A, mice pretreated withi4 8: mg/kg
 
amphetamine exhibited more locomotor activity than mice
 
pretreated with saline (see Fignre 5) [pretreatment; x time
 
interaction, F(56,910) =5.93, p < .001; and Tukey.tests, p
 
< .05]; Analyses involving only the wild-type mice showed
 
that pretreatment with the,two highest doses of amphetamine
 
(4 and 8 mg/kg) resulted in more locomotor activity on time
 
blocks 1-4 than saline pretreatment (see upper graph.
 
Figure 5) [pretreatment x time interaction, F(56,546) =:
 
5.77, p < .001; and Tukey tests, p < .05]. DiA-deficient
 
mice exhibited a more complex pattern of drug effects. For
 
example, Dia-deficient mice pretreated with 8 mg/kg
 
amphetamine exhibited more locomotor activity than saline
 
pretreated mice on time blocks 1 and 2 (see lower graph.
 
Figure 5) [pretreatment x time interaction, F(56,364) =
 
1.70, p < .01; and Tukey tests, p < .05]. On the other
 
hand, DiA-deficient mice pretreated with 4 mg/kg amphetamine
 
showed enhanced levels of locomotor activity across time
 
blocks 1-8. It is important to realize, however, that the
 
total amount of distance traveled did not vary between
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Figure 5. Mean ciistanGe traveled (±SEM) of adult wild-type and Dia­
deficient mice (n|= 7 - 8 per group) during testing (these are the same
 
mice as in Figures 1 and 2). Mice had previously received seven
 
consecutive injections of saline (SAL) or amphetamine (AMPH; 1.0, 2.0,
 
4.0, or 8.0 mg/kg, i.p.). After 3 abstinence days all mice received a
 
challenge injecticin of AMPH (1.0 mg/kg, i.p.). Behavioral testing
 
lasted for 150 min and occurred immediately after injection.
 
* Significantly different from the SAL group (p < .05).
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wild-type and biA-deficient mice [p > .05].
 
Test Day Stereotyped Sniffing: Three Abstinence Days.
 
After a three day abstinence period, amphetamine-pretreated
 
wild-type and Di^-deficient mice exhibited enhanced
 
stereotyped sniffing when compared to saline-pretreated
 
mice (see Figure^6) [pretreatment main effect, F(4,76) =
 
8.18, p < .001; and Tufcey tests, p< .05]. Specifically,
 
mice pretreated with 2, 4, or 8 mg/kg amphetamine, and then
 
challenged with 1 mg/kg amphetamine, had more stereotyped
 
sniffing counts than mice given amphetamine for the first
 
time on the test day. The stereotyped sniffing of wild-

type and DiA-deficient mice did not differ [p > .05].
 
Test Day Locomotor Activity: Seventeen Abstinence
 
days. After 17 drug abstinence days, both wild-type and
 
DiA-deficient mice showed a sensitized locomotor response :
 
(see Figure 7) [pretreatment main effect, F(56,770) = 5.57,
 
p < .001; and Tukey tests, p < .05]. More specifically,
 
wild-type mice pretreated with 4 or 8 mg/kg amphetamine had
 
more distance traveled on time blocks 1-3 than saline-

pretreated mice (see upper graph. Figure 7) [pretreatment x
 
time interaction, F(56,420) = 4.08, p < .001; and Tukey
 
tests, p < .05]. An almost identical pattern of effects ;
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deficient mice (n= 7 - 8 per group) during testing (these are the same 
mice as in Figures /i and 2) . Mice had previously received seven 
consecutive injections of amphetamine (AMPH; 1.0, 2.0, 4.0, or 8.0 
mg/kg, i.p. ) or saline (SAL) . After 3 abstinence days all mice 
received a challenge injection of AMPH (1.0 mg/kg, i.p.) . Behavioral 
testing lasted for 150 min and occurred immediately after injection. 
* Significantly different from the SAL group (p < .05) . 
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seven consecutive injections of saline (SAL) or amphetamine (T^PH;. 1.0, 
2.0, 4.0, or 8.0 mg/kg, i.p.) . After 17 abstinence days ail 
received a challenge injection of AMPH (1.0 mg/kg,. i.p. ) . Behavioral 
testing lasted for 150 min and occurred immediately after injection. 
* Significantly different from the SAL group (p < .05) . 
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was shown by Dia-deficient mice, with the only exception
 
being that the differences between the amphetamine (4 and 8
 
mg/kg) and "saline-pretreated mice were observed on time
 
blocks 1 and 2 (see lower graph. Figure 7) [pretreatment x
 
time interaction, F(55,350) = 2.59, p < .001; and Tukey
 
tests, p < .05]. The overall locomotor activity of wild-

type and DiA-deficient mice did not differ [p > .05].
 
Test Day Stereotyped Sniffing: Seventeen Abstinence
 
Days. After the extended abstinence period, only mice
 
pretreated with 2 mg/kg amphetamine exhibited a sensitized
 
sniffing response on the test day (see Figure 8)
 
[pretreatment main effect, F(4,59) = 3.44, p < .01; and
 
Tukey tests, p < .05]. The stereotyped sniffing of wild-

type and DiA-deficient mice did not differ, since the main
 
effect and interactions involving genotype as a variable
 
did not reach statistical significance.
 
Summary
 
These results indicate that DiA-deficient and wild-type
 
mice exhibit both short- and long-term behavioral
 
sensitization after repeated amphetamine treatment. This
 
suggests that the DA Dia receptor subtype is not necessary
 
for amphetamine-induced behavioral sensitization.
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Figure 8. Mean stereotyped sniffing (±SEM) of adult wild-type and Di^­
deficient mice (n =6 - 7 per group) during the second test day (these
 
are the same mice as iri Fighres 1 hhd 2). Mice had previously received
 
seven consecutive injections of saline (SAL) or amphetamine (AMPH; l.Q/
 
2.0, 4.0, or 8.0 mg/kg, i.p.).. After 17 abstinence days all mice
 
received a challenge injectipn of AMPH (1.0 mg/kg,: i.p.). Behavioral
 
testing lasted for 150 min and;occurred immediately after injectibh.
 
* Significantly different from the SAL group (p < .05).
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 EXPERIMENT 2
 
; Previous studies have shown that DA Di-like receptors ^
 
are irnportant for arriphetamine-induced locomotor
 
sensitization (Bjij[ou et ali,^ 1996; Crawford,et al;, 1997;
 
Vezina, 1996). Furthermore, several studies have emphasized
 
the importance of environmental cues and conditioning
 
factors for the development of behavioral sensitization
 
(Badiani et al., 1997; Badiani, Anagnostaras, & Robinson,
 
1995; Badiani, Browman, & Robinson, 1995). The purpose of
 
Experiment 2 was to determine whether the DA Dia receptor is
 
necessary for the environmental conditioning effects
 
typically observed in amphetamine-induced sensitization. 1
 
predicted that drug-paired environmental cues enhanced the
 
amphetamine-induced behavioral sensitization of wild-type,
 
but not DiA-deficient mice. This pattern of results would
 
indicate that the Dia receptor is necessary for environmental
 
conditioning effects.
 
Method ■ ; 
Iects. Subjects were 67 male and female C57BL-6 Dia­
deficient and wild-type mice 
Procedure. The apparatus and procedure described in
 
the General Methods were used with the following exceptions,
 
Animals received either amphetamine (8.0 mg/kg, i.p.) or
 
saline prior to being placed in the activity chamber.
 
Behavior was assessed for 6G min. Prior to being returned
 
to the home cage, mice were injected with either amphetamine
 
(8.0 mg/kg, i.p.) or saline. Specifically, mice injected
 
with amphetamine prior to being placed in the testing
 
chamber were injected with saline prior to being returned to
 
the home cage; whereas, mice injected with salineiprior to
 
being placed in the testing chamber were injected with
 
amphetamine prior to being returned to the home cage. The
 
pretreatment phase lasted for seven days. After three
 
abstinence days, mice were challenged with 1.0 mg/kg
 
amphetamine in the testing chamber. Locomotor activity and
 
stereotyped sniffing were assessed for a total of 150 min.
 
To assess conditioned activity, all mice were injected
 
with saline one day after the first test day. On the second
 
test day, locomotor activity and stereotyped sniffing were
 
assessed for 60 min. In summary, DiA-deficient and wild-type
 
mice received one of the following three sequences (PRE­
POST/TEST DAY l/TEST DAY 2) of drugs during the pretreatment
 
phase and on the first and second test day (injection
 
location is in parentheses): SAL(chamber)­
SAL(home)/AMPH/SAL, SAL(chamber)-AMPH(home)/AMPH/SAL, or
 
AMPH(chamber)-SAL(home)/AMPH/SAL.
 
Results
 
Locomotor Activity On Test Day 1 (Amphetamine
 
Challenge): Behavioral Sennitization., Pretreatment
 
condition interacted with genotype to affect the locomotor
 
activity of the mice (see Figure 9) [pretreatment condition
 
X genotype ■interaction, R (2,36) ,= 4 .19, p < .05; and Tukey; 
tests, p < .05] . Wild-type mice exhibited a sensitized 
locomotor response, but only if amphetamine pretreatment 
was given in the test chamber (see upper graph. Figure 9) 
[pretreatment condition x time interaction, F(28,280) = 
4.94, p < .001; and Tukey tests, p < .05] . More 
specifically, wild-type mice pretreated with 8 mg/kg 
amphetamine in the test chamber {filled squares) , and 
challenged with 1 mg/kg amphetamine, exhibited more 
locomotor activity on time blocks 1 and 2 than did mice 
acutely challenged with amphetamine on the test day {open 
circles) . Wild-type mice pretreated with amphetamine in 
the home cage (open squares) did not differ from saline-
pretreated controls (open circles) [p > .05] . 
DxA-deficient mice pretreated with amphetamine in the 
test chamber also exhibited more test day locomotor 
activity than saline-pretreated mice (see lower graph. 
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Figure 9. Mean distan^^^^ traveled (±SEM) of aduit wild-type and
 
■deficieril: 	 - 8 per group) during this first test; day. Mice 
had preyiously received seven daily injections of saline (SAL) or 
amphetamine (AMPH; 8. 0 mg/kg, i.p.) in either their hom^ cage -or iii the 
test chamber. ^ A 3 abstinence days all mice received a challenge 
ihjectidn of AMPH (1vO mg/kg, i.p.) in the testing chamber. Behavioral 
testing lasted for 150:jnih and occurred immediately after;injection:: 
* Significantly diffeireht from t^ SAL group (p < .05) . , 
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Figure 9) [pretreatment condition x time interaction,
 
F(28,244) = 1.93, p < .01; and Tukey tests, p < .05]. This
 
effect was more robust in DiA-deficient mice than with wild-

types, since significant differences:were apparent on time
 
blocks 1-8. Unlike wild-type mice, DiA-deficient mice
 
showed a sensitized locomotor response if amphetamine
 
pretreatment was given in the home cage [pretreatment
 
condition main effect, F(2,16) = 7.58, p < .01; and Tukey
 
tests, p < .05]. Even so, DiA-deficient mice pretreated
 
with amphetamine in the test chamber {filled squares) had
 
larger distance traveled scores than DiA-deficient mice
 
given amphetamine in the home cage {open squares).
 
Stereotyped Sniffing On Test Day 1 (Amphetamine
 
Challenge); Behavioral Sensitization. Dia-deficient mice
 
had significantly more test day sniffing counts than wild-

type controls (see Figure 10) [genotype main effect,
 
F(l,36) = 5.80, p < .05]. The differences between Dia­
deficient and wild-type mice were only observed in those
 
groups given amphetamine pretreatment (in either the test
 
chamber or home cage). Overall, mice given 8 mg/kg
 
amphetamine in the test chamber had significantly more test
 
day sniffing counts than saline-pretreated mice, with mice
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Figure 1.0. Mean stereotyped sniffing (±,SEM) of adult wild-type and Dia­
deficient mice (n = 6 - 8 per group) ■ during the first test day. Mice ' ; 
had previously received seven daily injections of saline (SAEi) or ^ 
amphetamine (AMPH;; 8.0 mg/kg, i.p.) in either their home cage or in the 
test chamber. After 3 abstinende days all mice;received a challenge 
injection of AMPH (1.0 mg/kg, i.p.) in the testing cha;mber. Behavioral 
testing lasted for 150 min and occurr^^ immediately after injection. 
* Significantly different;from the SAL group (p < ;.05). > \
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 given amphetamine in the home cage being intermediate
 
[pretreatment condition main effect, F(2,36) = 68.34, p <
 
.001].
 
Locomotor Activity On Test Day 2 (Saline Challenge);
 
Conditioned Activity. After a challenge injection of
 
saline, DiA-deficient mice had larger distance traveled
 
scores than wild-type mice (see Figure 11) [genotype main
 
effect, F(l,36) = 6.83, p < .05]. The enhanced locomotor
 
activity exhibited by Dia-deficient mice only occurred in
 
groups that had been pretreated with amphetamine. More
 
specifically, DiA-deficient mice pretreated with 8 mg/kg
 
amphetamine (in either the home cage or test chamber)
 
exhibited more locomotor activity than saline-pretreated
 
mice (see lower graph. Figure 11) [pretreatment condition x
 
time interaction, F(10,80) =2.14, p < .05; and Tukey
 
tests, p < .05]. The differences between amphetamine- and
 
saline-pretreated DiA-deficient mice reached statistical
 
significance on time blocks 1-4. In contrast, wild-type
 
mice pretreated with amphetamine did not show any
 
conditioned activity (see upper graph. Figure 11).
 
Stereotyped Sniffing On Test Day 2 (Saline Challenge);
 
Conditioned Sniffing. After receiving a challenge
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Figure 11. Mean distance traveled (iSEM) of adult wild-type and Dia­
deficient mice (n = 6 - 8, per group) during the second test day. Mice 
had previously received seven daily injections of saline (SAL) or 
amphetamine (AMPH; 8.0 mg/kg) in either their home cage or in the test 
chamber. After 4 abstinence days all mice received a challenge-
injection of SAL in the testing chamber to assess conditioned activity. 
Behavioral testing Tasted for 60 miri and gccurred immediately after the 
second injection. * Significantly different from the SAL group (p < 
.OS)-. ' '■ 
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injection of saline, diA-deficient mice sniffed more than
 
wild-type mide (see Figure 12) [genotype main effect,
 
F(1,36) = 5.42, p < .05]. The differences hetween the Dia­
deficient and wild-type mice were only apparent after
 
amphetamine pretreatment. Mice pretreated with 8 mg/kg
 
amphetamine in the test chamber, but not in the home cage,
 
had significantly more stereotyped sniffing counts than
 
saline-pretreated mice [pretreatment condition main effect,
 
F(2,36) = 14.71, p < .001]. Therefore, both DiA-deficient
 
and wild-type mice showed conditioned sniffing, but the
 
effect was more robust in DiA-deficient mice.
 
Summary
 
These results indicate that both wild-type and Dxa­
deficient mice show more robust behavioral sensitization
 
when amphetamine is given in the test chamber (i.e.,
 
Pavlovian associations are allowed to form) than in the
 
home cage. Wild-type mice did not show conditioned
 
activity, whereas DiA-deficient mice showed an exaggerated
 
locomotor response regardless,of whethe.r amphetamine
 
pretreatment occurred in the test chamber or home cage. :
 
The latter result suggests that PiA-deficient mice are not
 
showing true 'conditioned activity', but may only be
 
showing a generalized hyperactive response caused by
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Figure 12. Mean stereotyped sniffing counts (±SEM) of adult wild-type
 
and DiA-deficient mice ,(n = 6 - 8 per giroup) during the second test day.
 
Mice had previously received seven daily injections,of saline (SAL) or
 
amphetamine (AMPH; 8.0 mg/kg) in either their home cage or in the test
 
chamber. After 4 abstinehce days all mice received a challenge
 
injection of SAL (1.0 mg/kg) in the testing chamber to assess
 
conditioned sniffing. Behavioral testing lasted for 60 min and
 
occurred immediately after the second injection. > Significantly
 
different from the SAL group (p < .05).
 
59
 
amphetamine pretreatment.
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EXPERIMENT 3
 
Research has shown that DA Di-like receptors are
 
necessary for amphetamine-induced sensitization (Bjijou et
 
al., 1996; Vezina, 1996). By blocking DA Di-like receptors
 
with the putative DA Dx-like antagonist SCH-23390, locomotor
 
activity was reduced to control levels (Bjijou et al., 1996;
 
Vezina> 1996). However, because the Di-like family of
 
receptors is composed of two receptors, Dia and Ds, it is
 
uncertain whether the D5 receptor subtype is necessary for
 
amphetamine-induced sensitization. Therefore, in the
 
present experiment I pretreated DiA-deficient and wild-type
 
mice with SCH-23390 prior to their daily amphetamine
 
injections. I predicted that SCH-23390 pretreatment would
 
block amphetamine-induced sensitization in DiA-deficient
 
mice. The latter result suggested that the D5 receptor is
 
essential for:behavioral sensitization.
 
Method
 
Subjects. Subjects were 112 male and female C57BL-6 Dia­
deficient and wild-type mice.
 
Procedure. The apparatus and procedure described in
 
the General Methods were used with the following exceptions.
 
Subjects were given a preinjection of SCH-23390 (0.15, 0.5
 
or 1-5 mg/kg, i.p.) or saline 30 min prior to amphetamine
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 (8.0 mg/kg, i.p.) or saline injections. SCH-23390 injections
 
were given in the home cage, whereas amphetamine was given
 
prior to placement in the activity chamber. Behavioral
 
assessment lasted for 60-min and pccurred on seven
 
coriseGutive days. After three abstinence days, mice were
 
challenged with amphetamine (1.0 mg/kg, i.p.) or saline.
 
Locomotor activity and stereotyped sniffing were assessed
 
for a total of 150 min.
 
In summary, DiA-deficient and wild-type mice received
 
one of the following nine sequences (ANTAGONIST DRUG­
PRETREATMENT DRUG/TEST DAY DRUG) of SCH-23390, amphetamine
 
or saline during the pretreatment phase and on the test day
 
(doses are in parentheses): SAL-SAL/SAL, SAL-SAL/AMPH,
 
SCH(0.15)-SAL/AMPH, SCH(0.5)-SAL/AMPH, SCH(1.5)-SAL/AMPH,
 
SAL-AMPH/AMPH, SCH(0.15)-AMPH/AMPH, SCH(0.5)-AMPH/AMPH, or
 
SCH(1.5)-AMPH/AMPH.
 
Results
 
, Drug Pretreatment Phase: Locomotor Activity. During the
 
drug pretreatment phase Dia-^deficient mice exliiblted more
 
locomotor activity than wild-type mice [genotype main
 
effect, F(1,96) = 27.74, p < .001]. The effects of
 
genotype interacted with pretreatment, since Dia-deficient
 
mice pretreated with amphetamine had substantially larger
 
■■ ' ::;-62 ■
 
distance traveled scores (M = 150,259 era collapsed across
 
the seven days) than araphetaraine-pretreated wild-type mice
 
(M = 41,507 era) [genotype x pretreati^©^ interaction, 
F(1,96) = 12.52, p < .001; and Tukey tests, p < .05]. In 
addition, Dia-deficient mice pretreated with saline traveled 
a greater distance (M =28,834 era) than similarly treated 
wild-type mice (M = 7,492 era) [Tukey tests, p < .05],:. The 
effects of genotype and pretreatraent condition varied 
according to antagonist (i.e., SCH-23390) treatment, so ■ 
those effects will be described in the subsequent 
subsections.
 
Amphetamine-pretreated mice. Amphetamine-pretreated Dia­
deficient mice had larger distance traveled scores than , ■ 
wild-type mice (see Figure 13) [genotype main effect, 
F(1,56) = 26.74, p < .001]. Not surprisingly, this effect 
varied according to antagonist treatment. Amphetamine-
pretreated wild-type mice given 0.15 rag/kg SCH-23390 
exhibited more locoraotor activity than the 0.5 and 1.5 
rag/kg SCH-23390 groups, with,the 0.0 rag/kg group being 
intermediate (see upper graph. Figure 13) [antagonist main 
effect, F(3,28) = 7.11, p < .001; and Tukey tests, p < 
.05]. The differences between the 0.0 rag/kg {open circles) 
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Figure 13. Mean distance traveled (±SEM) of adult wild-type and Dia­
deficient mice (n = 8 per group) pretreated with saline (SAL) :or the Di-
like antagonist SCH-23390 (SCH; 0.15, 0.5, ori1,5 mg/kg i>pv) fpllowed 
by an injection of amphetamine (8.0 mg/kg, i.p. ) 30 min lateri This 
injection regimen was admihistered for seven consecutive days. 
Behavioral assessment lasted for 60 min and occurred immediately after 
the second infection. * Significantly different from 0. 00 mg/kg SCH 
group (p< .05) . 
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and 0.5 mg/kg {filled diamonds) SCH-233390 groups reached
 
statistical significance on pretreatment days 6 and 7 (see
 
upper graph. Figure 13) [antagonist x day interaction,
 
F(18,168) = 2.79, p < .001; and Tukey tests, p < .05].
 
SCH-23390 also affected the locomotor activity of Dia­
deficient mice injected with amphetamine. For example,
 
amphetamine-pretreated DiA-deficient mice given 0.5 mg/kg
 
SCH-23390 {filled triangles) exhibited more locomotor
 
activity than amphetamine-pretreated mice given 0.0 mg/kg
 
SCH-23390 {open circles) (see lower graph. Figure 13)
 
[genotype x antagonist interaction, F(3,56) =2.97, p <
 
.001; and Tukey tests, p < .05]. Amphetamine-pretreated
 
DiA-deficient mice showed a dose-dependent increase in
 
locomotor activity as the pretreatment phase progressed
 
[pretreatment day main effect, F(6,168) = 10.06, p < .001;
 
and Tukey tests, p < .05].
 
Saline-pretreated mice. Saline-pretreated DiA-deficient
 
mice had larger distance traveled scores than wild-type
 
mice (see Figure 14) [genotype main effect, F(l,40) =
 
41.62, p < .001]. This effect varied according to
 
antagonist treatment. More specifically, saline-pretreated
 
wild-type mice given SCH-23390 (0.15, 0.5, or 1.5 mg/kg)
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!Figure'14; Mean distance traveled (±SEM) of adult wild-type and Dia­
deficient mice (n = 6 per group) pretreated with saline (SAL) or the Di-
like antagonist SCH-2339Q (SC^^ 0.15, 0.5, or 1.5 mg/kg, i.p. ) followed 
by an injection of SAL 30 min later. This injection regimen was 
administered for seven consecutive days. Behavioral assessment lasted 
for 60 min and ocGurred immediately after the second injection. 
* Significantly different from 0.00 mg/kg SCH group (p < .05) . 
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Mad smaller distance traveled Scores than mice given 0.0
 
mg/kg SCH-23390 {open circles) (upper graph, Figure 14)
 
[antagonist main effect, F(3,20) = 10.12, p < .001; and
 
Tukey tests, p < .05]. Thus, SCH-23390 depressed the
 
locomotor activity of saline-pretreated wild-type mice.
 
DiA-deficient mice exhibited a different pattern of drug
 
effects, since DiA-deficient mice given both saline and 0.15
 
mg/kg SCH-23390 {filled diamonds) exhibited more locomotor
 
activity than DiA-deficient mice given saline and 0.0 mg/kg
 
SCH-23390 {open circles) (see bottom graph. Figure 14).
 
Due to the large amount of variance, the latter effect only
 
reached statistical significance on pretreatment day 7
 
[antagonist x day interaction, F(18,120) = 1.70, p < .05;
 
and Tukey tests, p < .05].
 
Drug Pretreatment Phase: Stereotyped Sniffing. Overall,
 
DiA-deficient mice had more stereotyped sniffing counts than
 
wild-type mice during the drug pretreatment phase [genotype
 
main effect, F(1,96) = 15.11, p < .001]. Not surprisingly,
 
stereotyped sniffing was most prominent in amphetamine-

pretreated mice [pretreatment main effect, F(l,96) = 71.08,
 
p < .001; and Tukey tests, p < .05].
 
Amphetamine-pfetreated mice. 0^rerall, amphetamine­
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pretreated DiA^deficient mice sniffed more than wild-type
 
controls [genotype main effect, F(1,56) = 14.84;,; p < .001].
 
It is apparent, however, that, the latter effect;, was
 
entirely due to the :act of SCH-23390 (see Figure 15)
 
[genotype X antagonist interaction, F(3,56) = 3.98, p < .05;
 
end Tukey tests, p < .05]. Specifically, all doses of SCH­
23390 (0.15, 0.5, and 1.5;mg/kg) cku a significant
 
reduction in the stereotyped sniffing of amphetamine­
,pretreated wild-type mice (see upper graph. Figure 15)
 
[antagonist main effect, F(3,28) = 38.09, p < .001; and
 
Tukey tests, p < .05]. In contrast, only 1.5 mg/kg SCH­
23390 decreased the stereotyped sniffing of amphetamine-

pretreated DiA-deficient mice (see lower graph, Figure 15)
 
[antagonist main effect, F(3,28) = 5.38, p < .01; and Tukey
 
tests, p < .05].
 
Saline-pretreated mice. The stereotyped sniffing of
 
saline-pretreated DiA-deficient and wild-type mice did not
 
differ (see Figure 16). Nor was the stereotyped sniffing
 
of saline-pretreated DiA-deficient and wild-type mice
 
affected significantly by SCH-23390 pretreatment.
 
Test Day Locomotor Activity: Amphetamine Pretreatment
 
Groups. Genotype interacted with antagonist treatment to
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Figure 15. Mean stereotyped sniffing counts (±SEM) of adult wild-type 
and DiA-deficient mice (n = 8 per group) pretreated with saline (SAL) or 
the Di-like antagonist SCH-23390 (SCHi 0.15, 0.5, pr 1.5 mg/kg, i.p.) 
followed by an injection of amphetamine (8.0 mg/kg, i.pi) 3 0 min later. 
This injection regimen was administered for seven consecutive days. 
Behavioral assessment lasted for 60 min and .occurred immediately after 
the second injection. * Significantly different from; 0.00 mg/kg SCH 
group (p < .05) . 
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Figure 16.. Mean stereotyped sniffing counts (+SEM) of adult wild-type 
and DiK-deficient mice (n =6 per group) pretreated with saline (SAL) or 
the Di-like antagonist SCH-23390 (SCH; 0.15, 0.5, or 1.5 mg/kg, i.p.) 
followed by an injection of SAL 30 min later. This injection regimen 
was administered for seven consecutive days. Behavioral assessment 
lasted for 60 min and occurred immediately after the second injection. 
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 affect the locomotor activity of amphetamine-pretreated
 
mice (see Figure 17) [genotype x antagonist x time
 
interaction, F(42,784) = 2.35, p < .001; and Tukey tests, p
 
< .05]. The locomotor activity of amphetamine-pretreated
 
wild^type mice was affected by SCH-23390 (see upper graph.
 
Figure 17) [antagonist x time interaction, F(42,392) = 2.45,
 
p < .001; and Tukey tests, p < .05]. More specifically,
 
wild-type mice pretreated with both 0.5 mg/kg SCH-23390 and
 
amphetamine {filled triangles) exhibited significantly less
 
locomotor activity on time blocks 1-3 than wild-type mice
 
given 0.0 mg/kg SGH-23390 and:amphetamine (open oircles).
 
Thus, a moderate dose of SCH-23390 (0.5 mg/kg) was able to
 
attenuate the development of amphetamine-induced
 
sensitization in wild-type mice. The higher dose of SCH­
23390 (1.5 mg/kg) produced a decline in amphetamine-induced
 
activity, but this did not reach statistical significance.
 
The locomotor activity of amphetamine-pretreated Dia­
deficient mice was not significantly affected by SCH-23390
 
(see lower graph. Figure 17). Thus, there is no evidence
 
that SCH-23390 pretreatment blocked the development of
 
amphetamine-induced locomotor sensitization in DiA-deficient
 
mice.
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Figure 17. Mean distance traveled (±SEM) of adult wild-type and Dia­
deficient mice (n = 8 per group) during testing (these are the same 
mice as in Figures 11 and 13) . Mice had previously received seven 
consecutive injections of either Saline (SAL) or the D^-like antagonist 
SCH-23390 (SCH; 0.15, 0.50, or 1.5 mg/kg, i.p.) followed by a second 
injection of amphetamine/(is.0 mg/kg, i.p.) 3 0 min later. After 3 
abstinence days all mice received a challenge injection of AMPH (1.0 
mg/kg, i.p. ) . Behavioral testing lasted for 150 min and occurred 
immediately after second injection. * Significantly different from the 
0.0 mg/kg SCH group (p < .05) . 
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Test Day Locomotor Activity; Saline Pretreatment Groups.
 
Genotype and antagonist treatment interacted to affect the
 
distance traveled scores of saline-pretreated mice (see
 
Figure 18) [genotype x antagonist interaction, F(3,40) =
 
5.17, p < .01; and Tukey tests, p < .05]. In wild-type ;
 
mice, pretreatment with SCH-23390 alone (i.e., no
 
amphetamine was given during the pretreatment phase)
 
resulted in enhanced locomotor responding after acute
 
injection of 1 mg/kg amphetamine on the test day (see upper
 
graph. Figure 18). More specifically, wild-type mice
 
pretreated with both saline and SCH-23390 (0.5 or 1.5
 
mg/kg) exhibited more test day locomotor activity than mice
 
pretreated with only saline [antagonist main effect,
 
F(3,20) = 5.73, p < .001; and Tukey tests, p < .05]. SCH­
23390-pretreated DiA-deficient mice showed a similar pattern
 
of effects, but the results did not reach statistical
 
significance (see lower graph. Figure 18).
 
Test Day Stereotyped Sniffing. Amphetamine pretreatment
 
produced a robust sensitized sniffing response (see Figure .
 
19). More specifically, mice pretreated with 8 mg/kg
 
amphetamine, and challenged with 1 mg/kg amphetamine,
 
exhibited more stereotyped sniffing than mice acutely
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Figure 18. Mean distance traveled (±SEM) of adult wild-type and Dia­
deficient mice (n = 6 per group) during testing (these are the same 
mice as in Figures 12 and 14) . Mice had previously received seven 
consecutive injections of either saline (SAL) or the Pi-like antagonist 
SCH-23390 (0.15, 0.50, or 1.5 mg/kg, i.p. ) followed by an injection of 
SAL 30 min later. After 3 abstinence days all mice received a 
challenge injection of AMPH (1.0 mg/kg, i.p. ) . Behavioral testing 
lasted for 150 min and occurred immediately after injection. 
* Significantly different from the 0.0 mg/kg SCH group (p < .05) . 
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Figure 19. Mean stereotyped sniffing counts (±SEM) of adult wild-type
 
and DiA-deficient mice (n = 6 - 8 per group) during testing (these are
 
the same mice as in Figures 11, 12, 13, and 14). Mice had previously
 
received seven consecutive injections of either saline (SAL) or the Di-

like antagonist SCH-23390 (SCH; 0.15, 0.50, or 1.5 mg/kg, i.p.)
 
followed by an injection of SAL or amphetamine (8.0 mg/kg, i.p.) 30 min
 
later. After 3 abstinence days all mice received a challenge injection
 
of AMPH (1.0 mg/kg, i.p.). Behavioral testing lasted for 150 min and
 
occurred immediately after injection.
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challenged with amphetamine on the test day [pretreatment
 
main effect, F(1,96) = 23.26, p < ,001]. Neither genotype
 
nor SCH-23390 pretreatment affected the overall pattern of
 
these results [p > .05].
 
Summary
 
These results indicate that DiA-deficient mice do not
 
require stimulation of either member of the Di-like family
 
of receptors to exhibit amphetamine-induced behavioral
 
sensitization. In contrast, wild-type only exhibit
 
amphetamine-induced behavioral sensitization if the Di-like
 
receptor system is functional.
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DISCUSSION
 
Previous research has indicated that the DA Di-like
 
family of receptors is important for behavioral
 
sensitization (Bjijou et al,, 1996; Crawford et al,, 1997;
 
Vezina, 1996). The purpose of the present study was to
 
determine whether a specific member of the Di-like receptor
 
family, the DA Dia receptor subtype, is necessary for
 
amphetamine-induced behavioral sensitization. As
 
predicted, chronic amphetamine treatment produced a
 
sensitized behavioral response in wild-type mice. In fact,
 
wild-type mice given repeated injections of amphetamine
 
showed both sensitized locomotor activity and stereotyped
 
sniffing when tested after 3 and 17 abstinence days (see
 
Figures 3, 4, 5 and 6). Importantly, chronic amphetamine
 
treatment also produced a sensitized locomotor response in
 
DiA-deficient mice (see lower graphs. Figures 3, 5 and 7).
 
Although contrary to my original hypotheses, the
 
latter results are not surprising because Crawford et al.
 
(1997) have reported that DiA-deficient mice exhibit
 
amphetamine-induced locomotor sensitization after three
 
abstinence days. The present results extend the findings
 
of the Crawford et al. (1997) study in two important ways.
 
First, the present study is the first to show that Dia­
77
 
deficient mice will exhibit sensitization offa stereotyped
 
behavior (i.e.^ .stereotyped sniffing:) Second/ this is the
 
first study to show that the sensitized locomotion and
 
sniffing exhibited by DiA-deficient mice will persist across
 
an exteiT-d.ed drug abstinence period (i.e., 17 days).
 
.Therefore,fwhen these results are considered together, it
 
is apparent that the Dia receptor is not necessary for
 
either;the short- or.long-term expression of amphetamine-

induced behavioral sensitization.
 
An additional purpose of this study was to determine
 
whether the associative learning processes involved in
 
.behavioral sensitization require a functioning Dia receptor
 
system. As predicted, wild-type mice pretreated with
 
amphetamine in the testing chamber exhibited sensitized
 
locomotor activity and sniffing (see upper graphs. Figures
 
9 and 10). Wild-type mice did not exhibit behavioral
 
sensitization when amphetamine pretreatment occurred in the
 
home cage. As with wild-type mice, DiA-deficient mice
 
showed m.ore robust behavioral sensitization when
 
amphetamine-pretreatment occurred in the testing chamber;
 
however, only DiA-deficient mice exhibited sensitized
 
locomotor activity and sniffing when amphetamine
 
pretreatment occurred in the home cage (see lower graphs.
 
Figures 9 and 10) Therefore, these data suggest that
 
conditioning factors (i.e., Pavlovian associations) are :
 
less important for DiA-deficient mice than for wild-type
 
controls (i.e., only DiA-deficient mice exhibited behavioral
 
sensitization when amphetamine was not paired with the test
 
chamber).
 
This conclusion is only tentative, since DiA-deficient
 
mice showed more TObust; c^^^ activity than wild-type
 
;cohtrpls. : Spbct^ wild-type mice did not exhibit
 
conditioned activity when saline was administered on the
 
second test day (see upper graph, Figure 11), and only
 
exhibited conditioned sniffing when amphetamine
 
pretreatment was given in the test chamber, but not in the
 
home cage (see Figure 12). In contrast, amphetamine-

pretreated DiA-deficient mice showed pronounced conditioned
 
locomotion and sniffing (see Figures 11 and 12). This
 
effect was very complex, however, since conditioned effects
 
were observed when DiA-deficient mice received amphetamine
 
in either the home cage or test chamber. Thus,
 
amphetamine-pretreated DiA-deficient mice showed
 
"conditioned" activity and sniffing regardless of whether
 
amphetamine was actually paired with the testing chamber.
 
Hence, rather than producing true conditioned activity.
 
amphetamine pretreatttient in the home cage might simply have
 
caused an exaggerated responsiveness in Dia-^deficient mid
 
(i.e., Pavlovian associations may have only been partly
 
responsible for the increased locomotor activity exhibited
 
by saline-challenged DiA-deficient mice).
 
A final goal of this study was to determine whether
 
the Other member of the Di-like receptor family, the DA D5
 
receptor subtype, was necessary for amphetamine-induced
 
behavibral sensitization. To that jend, wild-type and Dia­
deficient mice were given daily pretreatment injeCtiohs of
 
the Di-like receptor antagonist SCH-23390. As predicted,
 
SCH-2339b (0.5 mg/kg) blocked the development of locornotor
 
sensitization in wild-type mice (see upper graph. Figure
 
17). This suggests that the Di family of receptors (either
 
the Dia or D5 receptor subtype) is important for behavioral
 
serisitization, SCH-23390 did not attenuate
 
the locomotor sensitization exhibited by DxA-deficient mice
 
(see lower graph. Figure 17). The most parsimonious
 
explanation is that neither the Dia nor D5 receptor subtypes
 
are necessary for the amphetamine-induced locomotor
 
sensitization of DiA-deficient mice; whereas, Di-like
 
receptors are necessary for the amphetamine-induced
 
locomotor sensitization of wild-type controls.
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These finding are novel and suggest many ideas: first,
 
DiA-receptors may not be important for long-term changes in
 
behavior (i.e., plasticity); second, Pavlovian associations
 
may not be as important to DiA-deficient mice as they are for
 
wild-type mice; third, it is possible that neither Dia nor D5
 
receptors are important for amphetamine-induced behavioral
 
sensitization in DiA-deficient mice; fourth, compensatory
 
mechanisms may be responsible for the amphetamine-induced
 
behavioral sensitization exhibited by DiA-deficient mice;
 
and, fifth, the behaviors locomotor :
 
activity, sensitized stereotyped sniffing, exaggerated
 
conditioned activity etc...) exhibited by DiA-deficient mice
 
may have been influenced by a lack of dynorphin.
 
DA Dia Receptor Involvement in Amphetamine Sensitization
 
As previously reported, Dx-like receptor antagonists
 
block amphetamine- and- cocaine-induced behavioral
 
sensitization (Bjijou et al., 1996; Kuribara, 1995; Vezina,
 
1996; Vezina & Stewart, 1989). Therefore, available
 
evidence suggests that stimulation of Di-like receptors is
 
necessary for the occurrence of amphetamine-induced
 
behavioral sensitization. Yet when DiA-deficient mice were
 
challenged with amphetamine, a sensitized response
 
persisted for up to 17 abstinence days. That DiA-deficient
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mice also showed a sensitized stereotyped sniffing response
 
is interesting, since Di-like receptor stimulation is
 
necessary for D2-like mediated behaviors (stereotyped
 
sniffing often requires a combination of Di-like and D2-like
 
receptor stimulation) (see Clark & White, 1987, for a
 
review). At the very least, it seems clear that the Dxa
 
receptor is not required to produce stereotyped sniffing in
 
Dia receptor-deficient mice.
 
DA D5 Involvement in Amphetamine-Induced Locomotor
 
SensitizatiOn
 
Both pretreatment and challenge day data present a
 
similar picture. That is, SCH-23390 pretreatment blocked
 
locoTriotor sensitization in wild-type mice> but not Dia­
deficient mice (see upper graph. Figure 17). During the
 
pretreatment phase, the higher doses of SCH-23390 (0.5 and
 
1.5 mg/kg) completely blocked amphetamine-induced locomotor
 
activity of wild-type mice (see upper graph. Figure 13).
 
This is consistent with the challenge day data, because 0.5
 
mg/kg SCH-23390; blocked the expression of locbmotdr
 
sensitization in amphetamine-challenged wild-type mice (see
 
upper graph. Figure 17).
 
In contrast, SCH-23390 pretreatment did not block the
 
amphetamine-induced locomotor activity of Dia-deficient
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mice.: This pattern of results is aisb consistent;with-

challenge day data, in that SCH-23390 pretreatment was
 
unable to block the expressioh of amphetamine-induced
 
locomotor sensitization in DiA-deficient mice (see lower
 
graph, Figure 17). So, DiA-deficieht and wild-type mice
 
exhibit distinctly different behavior patterns after
 
chronic amphetamine treatment. That is, DiA-deficient mice
 
do not need Dia or D5 receptor stimulation to exhibit
 
amphetamine-induced locomotor sensitization, whereas wild-

type mice require a functioning Di-like receptor system.
 
Originally, I hypothesized that if DiA-deficient mice
 
showed behavioral sensitization, the D5 receptor would play
 
a necessary role in mediating this effect. The data do not
 
support this hypothesis. Instead, it is apparent that Di-

like receptors are necessary for the locomotor
 
sensitization of wild-type mice, but that neither Dia nor D5
 
receptors are necessary for the locomotor sensitization of
 
Dia-deficient mice. Several explanations may account for
 
these results. First, SCH-23390 may have,a greater' affinity
 
for Dia, as opposed to D5 receptors. Thus, SCH-23390 may not
 
have fully antagonized D5 receptors, perhaps allowing them
 
to mediate sensitization in DiA-deficient mice. Second,
 
inherent in recombinant technology is the issue of
 
corapensation/ In this ca GGmparisatory.mechariis may-

have allpvtfed amphetamine-induced behavioral sensitization
 
to occur in the absence of Di-like receptors.
 
The Influence of Compensatory Mechanisms in PiA^Peficient
 
Mice .
 
The possibility that compensation may allOw Dia­
deficient mice to exhibit locomotor sensitization is
 
particularly interesting, because reports havssugge
 
role for compensation in several different knockout mice.
 
For instance, the C57BL-6 mouse strain: includes several
 
knockout mice, some of which lack the DA transporter, or
 
the Dxa/ D2, or D4 receptors (Drago, PadungGhaichot,
 
Domenico, Sc. Fuchs, 1998). The possibility of compensatory
 
mechanisms is plausible since Di-like receptbrs have, been
 
identified early in gestation in normal mice (i.e., during
 
embryogenesis), leaving the strong possibility that some
 
compensatory mechanism might have developed by adulthood in
 
these mice (Clifford et al., 1998; Drago et al., 1998).
 
Nonetheless, although behavioral data from the present
 
study strongly suggest the presence of compensatory
 
mechanisms in Dia-deficient mice, no compensatory mechanisms
 
(e.g., upregulated D5 receptors, dynorphin levels, changes
 
in D2-like receptor levels, etc.) have been discovered
 
(Drago et al., 1998).
 
D2-Like Receptor Involvement in Plasticity
 
It is interesting that SCH-23390 pretreatment blocked
 
the amphetamine-induced sniffing of wild-type mice during
 
the pretreatment phase, but was ineffective at attenuating
 
sniffing on the challenge day (see Figures 15 and 19).
 
These results suggest that the Di-like receptor is necessary
 
for the occurrence of stereotyped sniffing, but is not
 
necessary for the eventual expression of a sensitized
 
sniffing response. The pretreatment data are consistent
 
with the idea that Di-like receptor activation is needed for
 
the occurrence of D2-like receptor-mediated sniffing (Clark
 
& White, 1987), but the challenge day data make a powerful
 
statement that Di-like receptor activation may not be
 
necessary to produce the underlying neurobiological changes
 
(i.e., plasticity) required for a sensitized sniffing
 
response.
 
Conditioned Activity in Wild-Type and PiA-Peficient Mice
 
One of the more interesting findings of this study was
 
the robust locomotor activity exhibited by saline-

challenged DiA-deficient mice (see lower graph. Figure 11).
 
Specifically, DiA-deficient mice pretreated with, amphetamine
 
in either the testing chamber or home cage showed
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substantial amounts pflocqmotot activity after saline
 
challenge (i.e., more than saline-pretreated rats). This
 
effect was not observed in wild-type mice (see upper graph,
 
Figure 11)., Because robust locomotor activity was apparent
 
in DiA-deficient mice pretreated with amphetamine in the
 
home cage, it appears that non-associative mechanisms,
 
other than Pavlovian processes, were responsible for this
 
increased locomotor activity. One possibility is that a
 
generalized heightened responsiveness could have caused the
 
increased locomotion in saline-challenged Dia-deficient
 
mice. Thus, rather than showing increased locomotor
 
activity due to the presence of drug-paired environmental
 
cues, amphetamine-pretreated DiA-deficient mice may have
 
only been exhibiting a generalized heightened
 
responsiveness that would have been expressed in any
 
environment (see Tirelli & Terry, 1998, for a relevant .
 
discussion). Consistent with this idea, DiA-deficient mice
 
have been described as * hyperactive' in other reports
 
(Clifford et al., 1998).
 
Dj-Like Receptor Antagonism: Behavioral Evidence For
 
Receptor Uprequlation or Supersensitivity
 
Wild-type mice pretreated with 0.5 or 1.5 mg/kg SCH­
23390 alone (i.e., no amphetamine) showed enhanced
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locomotor activity when given an acute injection of
 
amphetamine on the test day (see upper graph, Figure 18).
 
The only plausible explanation;for this effect was that
 
chronic SCH-23390pretreatment caused an upregulation of Di-

like receptors in wild-type mice (see Giorgi, Pibiri, Loi,
 
& Corda, 1993; O'Boyle, Gavin, & Harrison, 1993).
 
Accordihg to this idea, a test day injection of amphetamine
 
had enhanced behavioral impact in SCH-23390-pretreated,
 
wild-type mice because of the increased number of Di-like
 
receptors. Conversely, SCH-23390-pretreated DiA-deficient
 
mice did not show a significant increase in amphetamine-

induced locomotor activity on the test day (see lower
 
graph. Figure 18), although a nonsignificant trend was
 
apparent. Because DiA-deficient mice lack Dia receptors,
 
only a drug-induced upregulation (or supersensitivity) of D5
 
receptors could have occurred. If SCH-23390 pretreatment
 
did result in an excess number of Ds receptors (or
 
supersensitiye. D5 receptors) dt was insufficient to
 
significantly alter the amphetamine-induced locomotor
 
activity of DiA-deficient mice.
 
The Role of Dynorphin in PiA-Peficient Mice
 
K-Opioid receptors are located on the presynaptic
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processes of DA neurons comprising the nigrostriatal and
 
mesolimbic pathways (see Figure 20) (Hyman, 1996; Steiner &
 
Gerfen, 1998). Dynorphin (or the endogemous,ligand of k-

opioid receptors) acts on these presynaptic receptors to
 
inhibit DA release in both the striatum and nucleus
 
accumbens (Di Chiara & Imperato, 1988; Spanagel, Herz, &
 
Shippenberg, 1992; Zaratin & Clarke, 1994). Importantly,
 
dynorphin levels are dramatically reduced in DiA-deficient
 
mice (Xu, Moratalla, Gold, Hiroi, Koob, Graybiel, &
 
Tonegawa, 1994),• thus DiA-deficient mice may have elevated
 
basal levels of striatal and accumbal DA. If true, this
 
excess DA may be responsible for the heightened
 
responsiveness exhibited by DiA-deficient mice (see lower
 
graph. Figure il)> This heightened responsiveness may have
 
produced a behavior pattern that mimics behavioral
 
sehsitization and/or conditioned activity. Thus, it is
 
interesting whether amphetamine sensitization would
 
disappear in DiA-deficient mice if dynorphin was replaced
 
and/or K-opioid receptors were stimulated.
 
Since an upregulation of D5 receptors have been
 
eliminated as a possible form of compensation in Dia­
deficient mice (see Figure 18), questions arise whether
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Figure 20. K-Opioid receptors are located on the presynaptic processes 
of DA neurons comprising the nigrostriatal and mesolimbic pathways. 
Dynorphin (the endogenous ligand of K-opioid receptors) acts on these 
presynaptic receptors to inhibit DA release in both the striatum and 
nucleus accumbens. Importantly, dynorphin levels are dramatically 
reduced in DiA-deficient mice, thus DiA-deficient mice may have elevated 
basal levels of striatal and accumbal DA. If true, this excess DA may 
be responsible for the heightened responsiveness exhibited by Dia­
deficient mice DYN = Dynorphin; DA = Dopamine; K = K-Opioid receptors; 
GABA = y-Amino Butyric Acid; EAA = Excitatory Amino Acid. 
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changes in dyndrphin ievel&.may: for this
 
compensation. As mentioned above, it is possible that the , 
lack of dynorphin may act as a compehsatory mechanism in 
Dia"deficient mice, allowing these mice to express 
amphetamine-induced behavioral sensitization without a 
functional Di-like receptor system. This is important , 
because Di-like receptors have been shown in several reports 
to have a central role in amphetamine-induced behaviors, as 
well as amphetamine sensitization. In addition, this 
proposed compensatory mechanism could be responsible for 
the hyperactivity evident in these mice, as well as the ■ 
heightened display of conditioned activity. Further 
experimentation may reveal how these behaviors were 
manifest and what role dynorphin plays in DiA-deficierit 
mice.
 
Summary
 
When taken together, the results of the present study
 
provide important evidence about the role of the Di-like
 
family of receptors in behavioral sensitization. For
 
example, neither the Dia nor the D5 receptor is necessary
 
for amphetamine-induced locomotor sensitization in Dia­
deficient mice, but the DA Di-like receptor system is needed
 
for locomotor sensitization in wild-type mice. DiA-deficient
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mice apparently have a compensatory mechanism, not
 
involving D5 receptors, that allows the development and
 
expression of behavioral sensitization. The sensitization
 
exhibited by DiA-deficient and wild-type mice is more robust
 
when drug-paired environmental cues are available (i.e.,
 
when drug pretreatment and drug challenge occur in the test
 
chamber). Interestingly, amphetamine-pretreated Dia­
deficient mice, unlike wild-type controls, show a
 
heightened behavioral responsiveness that is not due to
 
Pavlovian associations. Therefore, while both DiA-deficient
 
and wild-type mice are capable of showing amphetamine-

induced behavioral sensitization, these mice exhibit
 
interesting behavioral differences that are presumably due
 
to the lack of Dia receptors and/or compensatory mechanisms.
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